Calliditas Therapeutics (Formerly known as Pharmalink)

85 articles with Calliditas Therapeutics (Formerly known as Pharmalink)

• Calliditas Therapeutics' nomination committee for the AGM 2021

  11/27/2020

  Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021.   The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting on September 14, 2017 , consists of: · Patrick Sobocki, appointed by Stiftelsen Industrifonden

• Interim Report Q3, 2020

  11/12/2020

  On August 13th, we announced a €19.8m acquisition of a majority stake of 62.7% in Genkyotex, a publicly listed life science company in France.

• Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report

  11/11/2020

  On November 12, 2020 , at 07:00 am CET , Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas will also host a telephone conference, which will include a presentation of the results, on the same day at 2:30 pm CET . The event will be hosted by the company's CEO, Renée Aguiar-

• Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

  11/9/2020

  Calliditas Therapeutics AB announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy.

• Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial

  11/9/2020

  On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy.

• 

  Calliditas Eyes Approval for IgaN Treatment Following Positive Late-Stage Study Results

  11/9/2020

  Calliditas said Nefecon hit its primary endpoint by demonstrating a statistically significant reduction in urine protein creatinine ratio, UPCR or proteinuria, after nine months of treatment.

• Calliditas closes acquisition of a controlling interest in Genkyotex SA

  11/3/2020

  Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) today announced the closing of the acquisition of 62.7% of Genkyotex SA ("Genkyotex") (Euronext Paris & Brussels: FR0013399474 - GKTX) in an off-market transaction. On August 13, 2020 , Calliditas announced that it had entered into an agreeme

• Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020

  10/19/2020

  Calliditas Therapeutics AB announced upcoming presentations concerning Nefecon, its lead product candidate, at the American Society of Nephrology Kidney Week 2020 Reimagined conference, to be held virtually October 19-25, 2020.

• The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020

  10/1/2020

  Calliditas Therapeutics AB announced that the last visit of the 200th patient has taken place in Part A of the pivotal NeflgArd Phase 3 study

• Number of shares and votes in Calliditas Therapeutics - Sep 30, 2020

  9/30/2020

  During September, Calliditas Therapeutics AB has allotted 111,250 common shares within the company's warrant program issued in 2017.

• First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon

  9/8/2020

  Calliditas Therapeutics AB announced that the first patient in China has been randomized into confirmatory part of the NefIgArd Phase 3 trial by its partner, Everest Medicines.

• Calliditas appoints Group General Counsel

  8/25/2020

  Calliditas Therapeutics AB announced the appointment of Jonathan Schur as Group General Counsel, effective October 1, 2020.

• Calliditas Therapeutics: Interim Report Q2, 2020

  8/13/2020

  "In June we successfully closed a $90m U.S. IPO on NASDAQ, which including the greenshoe that was exercised in July, resulted in gross proceeds of $97m in total.

• Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA

  8/13/2020

  Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at €2.80 per share in an off-market transaction.

• Number of shares and votes in Calliditas Therapeutics - July 31, 2020

  7/31/2020

  During July, Calliditas Therapeutics AB has issued 706,676 common shares as a result of the exercise of the over-allotment option within the initial public offering on The Nasdaq Global Select Market and the concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States.

• Calliditas reorganizes its management team

  7/24/2020

  Calliditas Therapeutics AB announced that it has reorganized its management team.

• Exercise of Over-allotment Option and End of the Stabilization Period - July 02, 2020

  7/2/2020

  Citigroup Global Markets Inc., in its capacity as Joint Global Coordinator, notifies that the stabilization period relating to Calliditas Therapeutics AB 's American Depositary Shares, traded on The Nasdaq Global Select Market has ended and no further stabilization transactions will be effected.

• Number of Shares and Votes in Calliditas Therapeutics

  6/30/2020

  During June, Calliditas Therapeutics AB (publ) has issued 9,230,770 common shares as a result of the initial public offering on The Nasdaq Global Select Market in the United States and concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States.

• CEO Renée Aguiar-Lucander Exercises Warrants and Invests SEK 15.7m (Appr. USD 1.7m) in Calliditas

  6/22/2020

  Calliditas Therapeutics AB announced that its CEO Renée Aguiar-Lucander will exercise warrants granted pursuant to Calliditas' Warrant Program 2017/2020, which corresponds to an investment totaling SEK 15.7 million.

• Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States

  6/5/2020

  Calliditas Therapeutics AB announced the pricing of its initial public offering on The Nasdaq Global Select Market by way of a capital increase of 9,230,770 new common shares, consisting of a public offering of 8,306,770 common shares in the form of American Depositary Shares...